(Total Views: 427)
Posted On: 05/19/2020 4:17:54 PM
Post# of 72447
The term sheet was for OM and IBD.
https://www.sec.gov/Archives/edgar/data/13552...ix_10k.htm
Quote:
The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement.
https://www.sec.gov/Archives/edgar/data/13552...ix_10k.htm
(0)
(0)
